Pentagastrin
Also known as: AY-6608, Pentagastrin, Pentagastrin stimulation test, Peptavlon, PG, Synthetic gastrin, β-Ala-Trp-Met-Asp-Phe-NH2 (Boc-protected)
Source Pentagastrin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pentagastrin is a synthetic pentapeptide analogue of gastrin that has been used primarily as a diagnostic stimulus to provoke calcitonin release from thyroid C‑cells. The test helps identify medullary thyroid carcinoma (MTC) and guide surgical decisions. It is administered by injection and is no longer marketed for clinical use.
Mechanism of Action
Pentagastrin binds to the CCK2/gastrin receptor on enterochromaffin‑like cells in the stomach, activating phospholipase C and increasing intracellular calcium, which drives gastric acid secretion. The same receptor is present on thyroid C‑cells, where activation triggers calcitonin release, providing the basis for its use in stimulation tests.
What the Research Shows
Clinical literature describes pentagastrin as the classic agent for calcitonin stimulation testing in patients with thyroid nodules. A Scandinavian surgical series recommends total thyroidectomy when pentagastrin‑stimulated calcitonin exceeds 100 pg/ml. Recent endocrine reviews note that calcium infusion achieves comparable stimulation, and the diagnostic value of pentagastrin is debated because highly sensitive basal calcitonin assays are now available. Experimental work shows that the peptide xenin can inhibit pentagastrin‑induced acid secretion, underscoring its physiological relevance. Overall, evidence is confined to diagnostic contexts; therapeutic investigations are absent.
Reported Benefits
When used in a controlled stimulation test, pentagastrin reliably elevates calcitonin, allowing clinicians to detect occult MTC with a reported positive predictive value approaching 100 % at levels >100 pg/ml. The test can uncover disease in patients with normal basal calcitonin, influencing the timing of prophylactic thyroidectomy.
Limitations of the Evidence
Pentagastrin is no longer commercially available, limiting its practical use. Alternative stimulants such as calcium and newer ultra‑sensitive calcitonin assays reduce the necessity for pentagastrin testing. The literature provides no data on therapeutic efficacy, and the diagnostic utility is questioned in modern practice. Evidence is limited to observational and review articles rather than randomized trials.
Safety Considerations
Published abstracts do not detail adverse events specific to pentagastrin. As a potent gastric secretagogue, it can provoke nausea, flushing, and cardiovascular changes in some individuals, which is why administration is performed in monitored settings. Lack of recent safety data and the withdrawn status counsel caution and professional supervision when used.
How It Is Administered
Pentagastrin is administered by intravenous or subcutaneous injection, typically as a single bolus dose for calcitonin stimulation testing. Formulations are supplied as sterile solutions for parenteral use.
Routes of Administration
Goals & Uses
- Provocative test for medullary thyroid carcinomaDiagnostic/OncologyHigh
- Research tool for CCK-B receptor pharmacologyResearchModerate
- Evaluation of pheochromocytoma (historical)Diagnostic/EndocrinologyLow
- Diagnostic stimulation of gastric acid secretionDiagnosticHigh
- Gastric acid secretion stimulation (diagnostic)DiagnosticHigh
- Calcitonin stimulation test for medullary thyroid carcinomaDiagnosticHigh
Contraindications
- Known hypersensitivity to pentagastrinImmuneHigh
- Zollinger‑Ellison syndromeGastrointestinalHigh
- Inflammatory bowel disease (acute)GastrointestinalModerate
- Obstructive jaundice / biliary diseaseHepatobiliaryModerate
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to pentagastrin or excipientsAllergy/ImmunologyHigh
- Active gastrointestinal hemorrhageGastrointestinalHigh
- Active peptic ulcer diseaseGastrointestinalHigh
Adverse Effects
- Anaphylaxis / hypersensitivityImmunologicRare
- Dizziness / lightheadednessNeurologicUncommon
- HypotensionCardiovascularRareLow blood pressure
- Abdominal crampsGastrointestinalCommon
- FlushingVascularUncommonWarmth and redness of the skin
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Abdominal cramping / painGastrointestinalCommon
Drug Interactions
- Proton pump inhibitorsLow
- H2-receptor antagonists (e.g., ranitidine, famotidine)Moderate
- Beta-blockersLow
- Proton pump inhibitors (PPIs)High
- Anticholinergics (e.g., atropine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with severe hepatic or renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
- PediatricsAgeRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization; available for research purposes.
- United StatesInvestigationalNot FDA‑approved; used under IND for diagnostic studies.
- United KingdomInvestigationalNot licensed for clinical use; supplied for diagnostic research.
Previously approved in the US (Peptavlon) and other jurisdictions as a diagnostic agent; manufacturing was discontinued in the US and many other markets. No longer commercially available in most countries. Historical use for gastric acid testing and MTC screening.
Evidence & Sources
- Journal ArticleModerateBrauckhoff M, et al.2004-01-01T00:00:00.000000Z
- Journal ArticleModerateDando TM, Plosker GL2004-01-01T00:00:00.000000Z
- Journal ArticleModerateKiriakopoulos A, Giannakis P, Menenakos E2022-01-01T00:00:00.000000Z
- Journal ArticleModerateAdams MH, Ostrosky JD, Kirkwood CF1988-01-01T00:00:00.000000Z
- Journal ArticleModerateHoltermüller KH, Dehdaschti M1982-01-01T00:00:00.000000Z
- Journal ArticleModerateFeurle GE1998-01-01T00:00:00.000000Z
Frequently Asked Questions
What is the purpose of a pentagastrin stimulation test?
The test measures the rise in calcitonin after an intravenous bolus of pentagastrin. A marked increase suggests medullary thyroid carcinoma and helps decide whether thyroidectomy is indicated.
Is pentagastrin still available for clinical use?
No. The compound has been withdrawn from the market, and most centers now use calcium infusion or rely on highly sensitive basal calcitonin measurements instead.
How is pentagastrin given during the test?
A short‑acting solution is injected intravenously (or subcutaneously) under medical supervision, and calcitonin levels are drawn before and several minutes after administration.
Are there any risks associated with the test?
While specific adverse‑event data are scarce, pentagastrin can cause nausea, flushing, and transient blood‑pressure changes, so the test is performed in a monitored setting.
Can pentagastrin be used to treat stomach ulcers?
No therapeutic benefit has been demonstrated. Its role is limited to diagnostic stimulation of calcitonin; other drugs such as proton‑pump inhibitors are used for ulcer management.
What is Pentagastrin used for?
Pentagastrin is educationally associated with: Provocative test for medullary thyroid carcinoma, Research tool for CCK-B receptor pharmacology, Evaluation of pheochromocytoma (historical), Diagnostic stimulation of gastric acid secretion, Gastric acid secretion stimulation (diagnostic), Calcitonin stimulation test for medullary thyroid carcinoma. Educational only — not medical advice.
How is Pentagastrin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Pentagastrin?
Reported adverse effects include: Anaphylaxis / hypersensitivity, Dizziness / lightheadedness, Hypotension, Abdominal cramps, Flushing, Nausea and vomiting, Nausea, Abdominal cramping / pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pentagastrin?
Recorded contraindications: Known hypersensitivity to pentagastrin, Zollinger‑Ellison syndrome, Inflammatory bowel disease (acute), Obstructive jaundice / biliary disease, Pregnancy, Hypersensitivity to pentagastrin or excipients, Active gastrointestinal hemorrhage, Active peptic ulcer disease. Consult a qualified clinician before use.